News Archives - NeuroRx

News

Humanigen, NeuroRx Plan FDA Emergency Use Filings for COVID-19 Candidates

Mar 30, 2021 Genetic Engineering and Biotechnology News Two COVID-19 drug developers said they will seek emergency use authorizations (EUAs) from the FDA for their therapeutics following positive late-stage clinical results. Humanigen disclosed topline Phase III results showing that hospitalized patients who received lenzilumab and other treatments—including steroids and/or Gilead Sciences’ marketed drug Veklury® (remdesivir)—had a 54% greater […]

News

Which COVID-19 treatments are showing promise? A list of potential drugs

By Lia Eustachewich, NY Post The race is on to find a treatment that works to quash the coronavirus — as the deadly disease continues to spread across the globe. Here’s a list of the most promising treatments and potential vaccines for SARS-CoV-2, the virus that causes COVID-19. Remdesivir The experimental antiviral drug, made by Gilead Sciences, was […]

News

Relief, NeuroRx say emergency treatment with RLF-100 helps critically ill Covid patients

By Tova Cohen; Reuters TEL AVIV (Reuters) – Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said on Sunday. Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, or aviptadil, a synthetic form of […]

News

FDA approves expanded access to Wilmington company’s experimental Covid-19 therapy

By John George, Senior Reporter – Philadelphia Business Journal The Food and Drug Administration on Wednesday granted NeuroRx and partner Relief Therapeutics an expanded access protocol for their experimental treatment of respiratory failure in Covid-19 patients. The action means Covid-19 patients who are not eligible to enroll in the ongoing phase-II/III clinical trials for the therapy because of […]

News

Is There Another Coronavirus Treatment? What To Know About The Fast-Tracked Drug Aviptadil

A drug that mimics a peptide produced by the bowel has been fast-tracked by the Food and Drug Administration to treat COVID-19 lung inflammation, NeuroRx Inc. announced Wednesday. The drug protects cells believed to act as a gateway for the coronavirus to attack the lungs.

News

UCI to take part in clinical trial of drug for critically ill COVID-19 patients

“If successful, we hope that treatments such as Aviptadil may change the chances of survival for these patients,” says Dr. Richard Lee, who is leading the trial at UCI. Carlos Puma for UCI Health”

News

Relief Therapeutics, NeuroRx get FDA nod to start coronavirus trial Thompson Reuters

Thompson Reuters TEL AVIV, March 29 (Reuters) – The U.S. Food & Drug Administration has authorised the start of a mid-stage trial by U.S.-Israeli NeuroRx and Relief Therapeutics for the use of Aviptadil to treat Acute Respiratory Distress in coronavirus patients. The companies said on Sunday they are recruiting study sites and pharmacies to begin […]

Category: News